// <auto-generated/>
// Contents of: hl7.fhir.r4.core version: 4.0.1
// Minimum TypeScript Version: 3.7
// FHIR ValueSet: http://hl7.org/fhir/ValueSet/research-study-phase|4.0.1
/**
 * Codes for the stage in the progression of a therapy from initial experimental use in humans in clinical trials to post-market evaluation.
 */
export const ResearchStudyPhaseCodes = {
    /**
     * early-phase-1: Designation for optional exploratory trials conducted in accordance with the United States Food and Drug Administration's (FDA) 2006 Guidance on Exploratory Investigational New Drug (IND) Studies. Formerly called Phase 0.
     */
    EarlyPhase1: "early-phase-1",
    /**
     * n-a: Trials without phases (for example, studies of devices or behavioral interventions).
     */
    NA: "n-a",
    /**
     * phase-1: Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
     */
    Phase1: "phase-1",
    /**
     * phase-1-phase-2: Trials that are a combination of phases 1 and 2.
     */
    Phase1Phase2: "phase-1-phase-2",
    /**
     * phase-2: Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
     */
    Phase2: "phase-2",
    /**
     * phase-2-phase-3: Trials that are a combination of phases 2 and 3.
     */
    Phase2Phase3: "phase-2-phase-3",
    /**
     * phase-3: Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
     */
    Phase3: "phase-3",
    /**
     * phase-4: Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
     */
    Phase4: "phase-4",
};
//# sourceMappingURL=data:application/json;base64,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